Corrigendum

International Immunology, Vol. 21, pp. 1057–1063.

Anti-vascular endothelial growth factor (VEGF) specific activity of intravenous immunoglobulin (IVIg)

Maya Damianovich¹, Miri Blank¹, Anat Raiter², Britta Hardy² and Yehuda Shoenfeld¹,³

¹Department of Medicine B, Center for Autoimmune Diseases, Sheba Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Hashomer, Israel
²Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel-Aviv University, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel
³Incumbent of Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Tel-Aviv University, Israel

The authors wish to correct the wording of the following sentence on page 1062 of their article:

‘… The blood perfusion has not been significantly inhibited ($P = 0.06$). The presence of relatively low concentration of anti-VEGF antibodies in an IVIg preparation may lead to an expected more pronounced effect of affinity fractionated specific IVIg-anti-VEGF …’

should read:

‘… The blood perfusion was not significantly inhibited ($P = 0.06$), most probably due to the presence of a relatively low concentration of anti-VEGF antibodies in an IVIg preparation; however, using the affinity-fractionated specific IVIg-anti-VEGF antibodies, a more pronounced effect would be expected …’